Anavex Life Sciences Corp. (AVXL)

NASDAQ: AVXL · IEX Real-Time Price · USD

5.48

-0.23 (-4.03%)

At close: Jul 19, 2024, 4:00 PM

5.70

+0.22 (4.01%)

Pre-market: Jul 22, 2024, 7:21 AM EDT

Anavex Life Sciences Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Year Ending	TTM	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	2018 - 2005
Selling, General & Admin	11.24	12.04	13.07	9.02	5.86	6.85	Upgrade
Research & Development	38.76	43.72	37.92	32.98	25.23	22.26	Upgrade
Operating Expenses	49.99	55.76	50.99	42	31.09	29.11	Upgrade
Operating Income	-49.99	-55.76	-50.99	-42	-31.09	-29.11	Upgrade
Other Expense / Income	-9.57	-8.26	-3.37	-4.36	-4.83	-2.89	Upgrade
Pretax Income	-40.43	-47.5	-47.62	-37.64	-26.26	-26.21	Upgrade
Income Tax	0.17	0.01	0.36	0.27	0.02	0.08	Upgrade
Net Income	-40.59	-47.51	-47.98	-37.91	-26.28	-26.29	Upgrade
Shares Outstanding (Basic)	82	80	77	70	58	49	Upgrade
Shares Outstanding (Diluted)	82	80	77	70	58	49	Upgrade
Shares Change	5.31%	3.74%	10.18%	19.95%	18.99%	9.52%	Upgrade
EPS (Basic)	-0.51	-0.60	-0.62	-0.54	-0.45	-0.54	Upgrade
EPS (Diluted)	-0.51	-0.60	-0.62	-0.54	-0.45	-0.54	Upgrade
Free Cash Flow	-32.48	-27.79	-24.24	-30.38	-21.29	-18.53	Upgrade
Free Cash Flow Per Share	-0.39	-0.35	-0.32	-0.43	-0.37	-0.38	Upgrade
EBITDA	-40.43	-47.5	-47.62	-37.64	-26.26	-26.21	Upgrade
EBIT	-40.43	-47.5	-47.62	-37.64	-26.26	-26.21	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).